These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 25559287)

  • 21. Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.
    De Pauw I; Lardon F; Van den Bossche J; Baysal H; Fransen E; Deschoolmeester V; Pauwels P; Peeters M; Vermorken JB; Wouters A
    Mol Oncol; 2018 Jun; 12(6):830-854. PubMed ID: 29603584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia-Related Head and Neck Cancer.
    Montanuy H; Martínez-Barriocanal Á; Antonio Casado J; Rovirosa L; Ramírez MJ; Nieto R; Carrascoso-Rubio C; Riera P; González A; Lerma E; Lasa A; Carreras-Puigvert J; Helleday T; Bueren JA; Arango D; Minguillón J; Surrallés J
    Clin Cancer Res; 2020 Jun; 26(12):3044-3057. PubMed ID: 32005748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
    Lu H; Li X; Lu Y; Qiu S; Fan Z
    Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.
    D'Amato V; Rosa R; D'Amato C; Formisano L; Marciano R; Nappi L; Raimondo L; Di Mauro C; Servetto A; Fusciello C; Veneziani BM; De Placido S; Bianco R
    Br J Cancer; 2014 Jun; 110(12):2887-95. PubMed ID: 24823695
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Anisuzzaman AS; Haque A; Wang D; Rahman MA; Zhang C; Chen Z; Chen ZG; Shin DM; Amin AR
    Mol Cancer Ther; 2017 Apr; 16(4):729-738. PubMed ID: 28119490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
    Hickinson DM; Klinowska T; Speake G; Vincent J; Trigwell C; Anderton J; Beck S; Marshall G; Davenport S; Callis R; Mills E; Grosios K; Smith P; Barlaam B; Wilkinson RW; Ogilvie D
    Clin Cancer Res; 2010 Feb; 16(4):1159-69. PubMed ID: 20145185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
    Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combinatorial approaches targeting the EGFR family and c-Met in SCCHN.
    Wang D; Lu Y; Nannapaneni S; Griffith CC; Steuer C; Qian G; Wang X; Chen Z; Patel M; El-Deiry M; Shin DM; He X; Chen ZG; Saba NF
    Oral Oncol; 2021 Jan; 112():105074. PubMed ID: 33142224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of epithelial-mesenchymal transition by cetuximab via the EGFR-GEP100-Arf6-AMAP1 pathway in head and neck cancer.
    Matsumoto Y; Sakurai H; Kogashiwa Y; Kimura T; Matsumoto Y; Shionome T; Asano M; Saito K; Kohno N
    Head Neck; 2017 Mar; 39(3):476-485. PubMed ID: 27880014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours.
    Gazzah A; Boni V; Soria JC; Calles A; Even C; Doger B; Mahjoubi L; Bahleda R; Ould-Kaci M; Esler A; Nazabadioko S; Calvo E
    Eur J Cancer; 2018 Nov; 104():1-8. PubMed ID: 30278378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
    Yonesaka K; Zejnullahu K; Lindeman N; Homes AJ; Jackman DM; Zhao F; Rogers AM; Johnson BE; Jänne PA
    Clin Cancer Res; 2008 Nov; 14(21):6963-73. PubMed ID: 18980991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined SN-38 and gefitinib treatment promotes CD44 degradation in head and neck squamous cell carcinoma cells.
    Nanbu T; Umemura N; Ohkoshi E; Nanbu K; Sakagami H; Shimada J
    Oncol Rep; 2018 Jan; 39(1):367-375. PubMed ID: 29192320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives.
    Bauman JE; Duvvuri U; Thomas S; Gooding WE; Clump DA; Karlovits B; Wehbe A; Miller FR; Kim S; Sen M; Heron DE; Grandis JR; Argiris A
    Cancer; 2018 Oct; 124(19):3881-3889. PubMed ID: 30291796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Schedule-dependent interaction between temsirolimus and cetuximab in head and neck cancer: a preclinical study.
    Lattanzio L; Milano G; Monteverde M; Tonissi F; Vivenza D; Merlano M; Lo Nigro C
    Anticancer Drugs; 2016 Jul; 27(6):533-9. PubMed ID: 26982238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer.
    Bozec A; Ebran N; Radosevic-Robin N; Sudaka A; Monteverde M; Toussan N; Etienne-Grimaldi MC; Nigro CL; Merlano M; Penault-Llorca F; Milano G
    Laryngoscope; 2016 Apr; 126(4):E156-63. PubMed ID: 26597440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel multi-targeted ErbB family inhibitor afatinib blocks EGF-induced signaling and induces apoptosis in neuroblastoma.
    Mao X; Chen Z; Zhao Y; Yu Y; Guan S; Woodfield SE; Vasudevan SA; Tao L; Pang JC; Lu J; Zhang H; Zhang F; Yang J
    Oncotarget; 2017 Jan; 8(1):1555-1568. PubMed ID: 27902463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma.
    Kondo N; Tsukuda M; Ishiguro Y; Kimura M; Fujita K; Sakakibara A; Takahashi H; Toth G; Matsuda H
    Oncol Rep; 2010 Apr; 23(4):957-63. PubMed ID: 20204279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib.
    Taguchi T; Tsukuda M; Imagawa-Ishiguro Y; Kato Y; Sano D
    Oncol Rep; 2008 Jan; 19(1):65-71. PubMed ID: 18097577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck.
    Iberri DJ; Colevas AD
    Oncologist; 2015 Dec; 20(12):1393-403. PubMed ID: 26446236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergistic Growth Inhibition by Afatinib and Trametinib in Preclinical Oral Squamous Cell Carcinoma Models.
    Yee PS; Zainal NS; Gan CP; Lee BKB; Mun KS; Abraham MT; Ismail SM; Abdul Rahman ZA; Patel V; Cheong SC
    Target Oncol; 2019 Apr; 14(2):223-235. PubMed ID: 30806895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.